BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.
Company Details
- Employees
- 5
- Address
- 50 Milk Street, Boston,massachusetts 02110,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Boston, Massachusetts
Boston Immune Technologies And Therapeutics Questions
Boston Immune Technologies And Therapeutics's website is https://www.bostonimmunetech.com/
Boston Immune Technologies And Therapeutics's LinkedIn profile is https://www.linkedin.com/company/bostonimmunetech
Boston Immune Technologies And Therapeutics has
5 employees.
View email and phone details for 5
employees at Boston Immune Technologies And Therapeutics.
Boston Immune Technologies And Therapeutics's industry is
Biotechnology Research
Boston Immune Technologies And Therapeutics's top competitors are
Allgenesis Biotherapeutics Inc.,
Panolos Bioscience,
Camp Bernadette And Camp Fatima,
Poolbeg Pharmaceuticals,
Alnylam Pharmaceuticals,
Erica Wilson Inc,
Deepbiome Therapeutics Inc.,
Vellum Biotechnology,
Asymmetrex®, Llc,
Caliber Imaging & Diagnostics, Inc..
Boston Immune Technologies And Therapeutics's categories are Biotechnology Research
